Financials data is unavailable for this security.
View more
Year on year United Therapeutics Corp grew revenues 20.20% from 1.94bn to 2.33bn while net income improved 35.40% from 727.30m to 984.80m.
Gross margin | 88.94% |
---|---|
Net profit margin | 40.31% |
Operating margin | 46.42% |
Return on assets | 15.71% |
---|---|
Return on equity | 18.81% |
Return on investment | 17.73% |
More ▼
Cash flow in USDView more
In 2023, United Therapeutics Corp increased its cash reserves by 25.65%, or 246.50m. The company earned 978.00m from its operations for a Cash Flow Margin of 42.02%. In addition the company used 719.60m on investing activities and also paid 11.90m in financing cash flows.
Cash flow per share | 24.08 |
---|---|
Price/Cash flow per share | 15.18 |
Book value per share | 136.74 |
---|---|
Tangible book value per share | 134.23 |
More ▼
Balance sheet in USDView more
Current ratio | 4.58 |
---|---|
Quick ratio | 4.41 |
Total debt/total equity | 0.0656 |
---|---|
Total debt/total capital | 0.0615 |
More ▼